TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03290287

Intervention type: DRUG
Intervention: Aclidinium bromide
Description: Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol

Intervention type: DRUG
Intervention: Other COPD medication
Description: Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol
Study: NCT04239118

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
Description: Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional methods of endoscopic hemostasis
Description: Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
Study: NCT02773199

Intervention type: OTHER
Intervention: Preoperative Fasting for 8 hours
Description: Patients will be exposed to preoperative fasting

Intervention type: OTHER
Intervention: Preoperative Fasting for more than 12 hours
Description: Patients will be exposed to preoperative fasting

Intervention type: DRUG
Intervention: Spinal Anesthesia with Bupivacaine
Description: Spinal Anesthesia with heavy bupivacaine 0.5% is provided.

Intervention type: DRUG
Intervention: Spinal Anesthesia with Bupivacaine
Description: Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
Study: NCT02171390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone 250mg injection
Description: The testosterone 250mg ester intramuscular injections performed in three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosteron 50 mg transdermal gel
Description: 50mg testosterone gel implemented on every night
Study: NCT02678871

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
Description: Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)

Intervention type: DEVICE
Group type: OTHER
Intervention: WATCHMAN
Description: LAA closure with the WATCHMAN device
Study: NCT02056470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Total Knee
Description: The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement
Description: total Knee replacement implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Total Knee System
Description: Total Knee replacement implant
Study: NCT02841748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg, every three weeks, iv, x 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: iv, every three weeks, x 1 year
Study: NCT00359632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyvox - linezolid
Description: Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched control
Description: Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
Study: NCT04417582

Intervention type: PROCEDURE
Intervention: bariatric surgey
Description: patients undergone bariatric surgery or prescribed antiobesity drugs

Intervention type: PROCEDURE
Intervention: bariatric surgey
Description: patients undergone bariatric surgery or prescribed antiobesity drugs
Study: NCT01088919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet
Study: NCT00304135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02391350

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and re-assurance
Description: Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
Study: NCT02517151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01012505

Intervention type: OTHER
Intervention: adding pad with maternal milk in hte incubator
Description: 2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol
Study: NCT00304135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01088919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: oral tablet
Study: NCT02192606

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Storz 3D Laparoscopy System
Description: The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopy
Description: The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
Study: NCT01088919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: oral tablet
Study: NCT02207972

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Ultrasound
Description: The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound used
Description: Palpation of anatomical landmarks is used for placement of labor analgesia
Study: NCT03490357

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Transversus Abdominus Plane Block
Description: Abdominal fascial plane block - regional anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Abdominal fascial plane block - regional anesthesia
Study: NCT00553683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly ICLC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study: NCT02482441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-131R10
Description: There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-131R10
Description: There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
Study: NCT02068131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novaferon
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
Study: NCT05989035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Fatty tissue biopsy- Participant will be placed in a supine position with arms placed at side while abdominal skin is marked with a skin marker and cleansed with chlorhexidine. Afterwards, the abdominal fatty tissue biopsy will be performed.~Collect fatty tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that fatty tissue in the laboratory.
Study: NCT01714752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measure of left ventricular and diastolic pressure at exercise
Study: NCT01325324

Intervention type: DEVICE
Group type: OTHER
Intervention: measurement of intraocular pressure
Description: Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
Study: NCT00794092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinerem administration
Description: Single dose
Study: NCT00859833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
Study: NCT04084041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simeox
Description: Airway clearance device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simeox
Description: Airway clearance device
Study: NCT04281342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 100 mg
Description: Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.

Intervention type: OTHER
Group type: OTHER
Intervention: Moxifloxacin control to establish assay sensitivity
Description: Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
Study: NCT04365998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BUBOLight® Device
Description: 1 session of phototherapy with BUBOLight® device during 4 hours.
Study: NCT04084041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCPT
Description: Conventional chest physiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCPT
Description: Conventional chest physiotherapy
Study: NCT01463527

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nellcor NPB-70 Capnograph
Description: Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
Study: NCT03038243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)
Description: 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
Study: NCT01463527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor NPB-70 Capnograph
Description: Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
Study: NCT01088503

Intervention type: DRUG
Intervention: ADP receptor inhibitors
Description: Dosage regimen as determined by the treating physician.
Study: NCT02943694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaTME with CS-Compact (GelPoint pathway)
Description: Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
Study: NCT03259295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digiclamp (Skin tag removal initial plus follow-up)
Description: Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
Study: NCT03892317

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pharmacist led medication adherence interventions
Description: Medication adherence interventions which will be tailored to individual patient need
Study: NCT03038243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)
Description: 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)
Description: 2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine
Description: 2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine
Description: 2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a whole cell (Sf2aWC) vaccine
Description: 2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
Study: NCT02046525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline enema
Study: NCT00733369

Intervention type: DEVICE
Group type: OTHER
Intervention: PFC Sigma RP-F
Description: An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma RP
Description: An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
Study: NCT03528473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines.
Study: NCT04531657

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens

Intervention type: DRUG
Intervention: Influenza vaccine
Description: influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
Study: NCT03463993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
Study: NCT03425487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Intervention
Description: MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion based Intervention
Description: ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Usual specialized treatment in mental health (psychological or/and psychiatric)
Study: NCT02714933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI sequence Advanced ZTE
Description: Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
Study: NCT02972502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Patients receive 10 mg of intravenous (IV) metoclopramide.
Study: NCT01149395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dosage: 30 mg once per day for 4 weeks by mouth
Study: NCT02972502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Patients receive 2.5 mg of IV haloperidol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: All patients receive a 1-liter bolus of normal saline (NS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: All patients receive a 1-liter bolus of normal saline (NS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: All patients receive 25 mg of intravenous (IV) diphenhydramine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: All patients receive 25 mg of intravenous (IV) diphenhydramine.
Study: NCT02668848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Description: If USG\>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
Study: NCT01763918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT03038243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
Study: NCT03296865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed.